Quarterly report · Q2
4671.TEDINET S100S7JG
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥851m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥931m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥36.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥38.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥38.7bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥26.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥24.3bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥322m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥249m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥448m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥937m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥56.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.34 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.16 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥56.14 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥107.18 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 70.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥270m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥689m |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥385m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥46m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥213m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥15.9bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥15.9bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥320m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥293m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥293m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥99m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 539
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)ＰｗＣ 京 都 監 査 法 人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)浦 上 卓 也 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)鷺 谷 佑 梨 子 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 24151000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 21325000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 46913000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 1877000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 931000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 3310000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 1125000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 629000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 2261000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 1143000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 627000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 2296000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 24290000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 26032000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 26591000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 38680000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 36746000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 38893000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 107.50 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 56.29 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 215.29 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 107.18 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 56.14 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 214.03 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.626 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.706 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.682 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 1451000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 1660000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 2086000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -249000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -1851000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | 322000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -937000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -3237000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -448000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 10908000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 9174000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 12603000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 65.16 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 45.34 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 11280177 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |